For the year ending 2025-12-31, LRMR had $52,194K increase in cash & cash equivalents over the period. -$113,292K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Operating expenses | 172,497 |
| Other income, net | 6,824 |
| Net loss | -165,673 |
| Stock-based compensation expense | 7,004 |
| Lease expense | -281 |
| Depreciation expense | 350 |
| Amortization of premium on marketable securities | -1,698 |
| Prepaid expenses and other current assets | -6,680 |
| Accounts payable | 2,792 |
| Accrued expenses | 37,552 |
| Other assets | -73 |
| Net cash used in operating activities | -113,201 |
| Purchases of property and equipment | 91 |
| Purchases of marketable securities | 83,600 |
| Maturities of marketable securities | 184,000 |
| Net cash provided by (used in) investing activities | 100,309 |
| Proceeds from issuance of common stock, net of issuance costs | 65,086 |
| Net cash provided by financing activities | 65,086 |
| Net increase in cash, cash equivalents and restricted cash | 52,194 |
| Cash, cash equivalents and restricted cash at beginning of period | 33,824 |
| Cash, cash equivalents and restricted cash at end of period | 86,018 |
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)